Gagan Sawhney, MD
Ophthalmology · Atlanta, GANPI 1528380441
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $391,243 of the $581,690 with a category attached, or 67.3%. 34 manufacturers reported payments, led by AbbVie at 27.4% of the total. 2025 is the largest year on record at $188,963, 3.7 times the $50,436 reported in 2019. Among ophthalmology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,034 payments — averaging $562.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$159K
- Bausch & Lomb Americas Inc.$152K
- Alcon$92K
- Aerie Pharmaceuticals, Inc.$77K
- NEW World Medical,inc.$37K
- Sight Sciences, Inc.$19K
- plus $45K from 28 others
Across 101 payments — averaging $2995.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$154K
- Alcon Research LLC$86K
- Glaukos Corporation$53K
- NEW World Medical,inc.$10K
What the payments were for
- Consulting fees$107,91619%
- Speaking & faculty fees$391,24367%
- Travel & lodging$57,79910%
- Food & beverage$24,3854%
- Education$2400%
- Gifts$1070%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 265 | $159,463 |
| Bausch & Lomb Americas Inc. | 268 | $152,172 |
| Alcon | 149 | $91,937 |
| Aerie Pharmaceuticals, Inc. | 82 | $77,321 |
| NEW World Medical,inc. | 42 | $37,226 |
| Sight Sciences, Inc. | 64 | $18,556 |
| Glaukos Corporation | 24 | $17,542 |
| Ivantis, Inc | 21 | $10,582 |
| Nordic Pharma, Inc. | 2 | $8,400 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 20 | $4,355 |
| Lensar, Inc. | 1 | $1,200 |
| Novartis | 27 | $528 |
| Oyster Point Pharma, Inc. | 13 | $400 |
| Sun Pharmaceutical Industries Inc. | 7 | $268 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $216 |
| Biotissue Holdings Inc. | 4 | $199 |
| Harrow Eye, LLC | 9 | $199 |
| Amgen(2 entities) | 4 | $187 |
| ANI Pharmaceuticals, Inc. | 3 | $168 |
| Rxsight Inc | 3 | $165 |
| Genentech USA, Inc. | 1 | $141 |
| Tarsus Pharmaceuticals, Inc. | 3 | $92 |
| Thea Pharma Inc. | 3 | $85 |
| Mallinckrodt Hospital Products Inc. | 3 | $69 |
| Kala Pharmaceuticals, Inc. | 3 | $51 |
| Ocular Therapeutix, Inc. | 2 | $33 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Solta Medical, A Division Of Bausch Health US, LLC | 1 | $21 |
| Nova Eye, Inc. | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Iridex Corporation | 1 | $13 |
| Omeros Corporation | 1 | $12 |
| Akorn, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rocklatan$162,952
- Rhopressa$158,871
- VYZULTA$153,527
- DURYSTA$142,772
- Ahmed Glaucoma Valve$26,644
- Kahook Dual Blade$26,644
- SIMBRINZA$22,273
- OMNI(R) SURGICAL SYSTEM (US)$17,814
- Travoprost Intraocular Implant - iDose$16,220
- XEN$9,425
- Clearpath$8,425
- Streamline$8,425
- Lacrifill$8,400
- Hydrus$8,228
- Via360$5,310
- SION SURGICAL INSTRUMENT$4,132
- MIEBO$3,067
- XEN GLAUCOMA TREATMENT SYSTEM$2,439
- Hydrus Microstent$2,113
- LENSAR LASER SYSTEM$1,200
How this compares
$581,690 in reported general payments places this provider in the 95th percentile of 481 ophthalmology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 393 | $225,807 |
| XiidraLifitegrast | 163 | $206,856 |
| RhopressaNetarsudil Mesylate | 331 | $190,611 |
| VyzultaLatanoprostene Bunod | 266 | $157,972 |
| RestasisCyclosporine | 82 | $108,831 |
| RocklatanNetarsudil Mesylat/Latanoprost | 131 | $92,839 |
| CombiganBrimonidine Tartrate/Timolol | 233 | $87,914 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 140 | $33,420 |
| Alphagan PBrimonidine Tartrate | 58 | $30,829 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 92 | $23,972 |
| Brinzolamide | 87 | $19,277 |
| ProlensaBromfenac Sodium | 50 | $17,868 |
| Brimonidine Tartrate | 658 | $16,929 |
| Travoprost | 70 | $14,884 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 64 | $13,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $159,463 | $453,381766 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $152,172 | $364,828429 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $77,321 | $283,450462 claims |
| AlconSimbrinza | $91,937 | $23,97292 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $4,355 | $17,86850 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $268 | $12,92317 claims |
| NovartisIlevro | $528 | $11,55224 claims |
| Thea Pharma Inc.Iyuzeh | $85 | $7,74919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 481 ophthalmology providers in Georgia.
Other ophthalmology in Atlanta
- Lawrence WoodardAtlanta$578K
- Stephanie VanderveldtAtlanta$384K
- Steven YehAtlanta$289K
- Evan SchoenbergAtlanta$130K
- Robert StultingAtlanta$85K
- David SackelAtlanta$82K
- Atul SharmaAtlanta$77K
- Daniel MartinAtlanta$55K
- Douglas DayAtlanta$52K
- Jay StallmanAtlanta$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.